Damora Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

DMRA$24.07+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

ExhibitNumber	Exhibit Description	Incorporated by ReferenceHerein from Form or Schedule	Filing Date	SEC File / Reg. Number
2.1†	Agreement and Plan of Merger, dated November 10, 2025, by and among the Registrant, Daylight Merger Sub I, Inc., Daylight Merger Sub II, LLC and Damora Therapeutics, Inc.	Form 8-K (Exhibit 2.1)	November 10, 2025	001-39655
2.2	Plan of Conversion.	Form 8-K (Exhibit 2.1)	July 20, 2026	001-39655
3.1	Cayman Memorandum and Articles of Association.	Form 8-K (Exhibit 3.1)	July 20, 2026	001-39655
3.2	Cayman Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Shares.	Form 8-K (Exhibit 3.2)	July 20, 2026	001-39655
3.3	Cayman Certificate of Designation of Preferences, Rights and Limitation of Series B Non-Voting Convertible Preferred Shares.	Form 8-K (Exhibit 3.3)	July 20, 2026	001-39655
3.4	Cayman Certificate of Designation of Preferences, Rights and Limitation of Series C Non-Voting Convertible Preferred Shares.	Form 8-K (Exhibit 3.4)	July 20, 2026	001-39655
10.1#	Form of Indemnification Agreement for directors and officers.	Form 8-K (Exhibit 10.1)	July 20, 2026	001-39655
10.2#*	Amended and Restated Damora Therapeutics, Inc. 2020 Stock Option and Grant Plan.
10.3#*	Amended and Restated Damora Therapeutics, Inc. 2020 Equity Incentive Plan.
10.4#*	Amended and Restated Damora Therapeutics, Inc. 2022 Inducement Plan.
10.5#*	Form of Option Award Agreement under the Amended and Restated Damora Therapeutics, Inc. 2022 Inducment Plan.
10.6#*	Form of Restricted Stock Unit Agreement under the Amended and Restated Damora Therapeutics, Inc. 2022 Inducment Plan.
10.7#*	Amended and Restated Damora Therapeutics, Inc. 2025 Equity Incentive Plan.
10.8#*	Amended and Restated Damora Therapeutics, Inc. 2026 Equity Incentive Plan.
10.9#*	Form of Employee Option Award Agreement under the Amended and Restated Damora Therapeutics, Inc. 2026 Equity Incentive Plan.
10.10#*	Form of Director Option Award Agreement under the Amended and Restated Damora Therapeutics, Inc. 2026 Equity Incentive Plan.
10.11#*	Amended and Restated Damora Therapeutics, Inc. 2026 Employee Stock Purchase Plan.
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

ExhibitNumber	Exhibit Description	Incorporated by ReferenceHerein from Form or Schedule	Filing Date	SEC File / Reg. Number
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**††	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL (extensible Business Reporting Language) Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Filed herewith.

** Furnished herewith.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.